Загрузка...
Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...
Сохранить в:
| Опубликовано в: : | Intern Med |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Japanese Society of Internal Medicine
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/ https://ncbi.nlm.nih.gov/pubmed/29526929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|